Journals / Pamukkale Tıp Dergisi / 2023 / Cilt: 16 Sayı: 4

The effects of reoperations due to inadequate treatment in differentiated thyroid cancers on morbidity, mortality and costs

Diferansiye tiroid kanserlerinde yetersiz tedavi nedeniyle yapılan reoperasyonların morbidite, mortalite ve maliyetlere etkisi

Pages
736–741
Publication Date
2023-10-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, even in low and intermediate risk DTC cases, adequate surgeries such as total or near total thyroidectomy should be performed by high volume endocrine surgeons and moderate TSH suppression should be applied in all cases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although the incidence of differentiated thyroid cancer (DTC) is high, mortality is quite low.
📊
Key Findings & Data:In low and intermediate risk DTCs, reoperations due to inadequate treatment can increase morbidity, mortality, and costs in patients.
💡
Conclusion & Impact:Therefore, even in low and intermediate risk DTC cases, adequate surgeries such as total or near total thyroidectomy should be performed by high volume endocrine surgeons and moderate TSH suppression should be applied in all cases.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Etkileri · reoperasyonlar · diferensiye

Abstract

Although the incidence of differentiated thyroid cancer (DTC) is high, mortality is quite low. In low and intermediate risk DTCs, reoperations due to inadequate treatment can increase morbidity, mortality, and costs in patients. In our study, current articles published on this subject were reviewed and evaluated. According to our results, morbidity, mortality and costs increase due to inadequate treatment in DTCs. Therefore, even in low and intermediate risk DTC cases, adequate surgeries such as total or near total thyroidectomy should be performed by high volume endocrine surgeons and moderate TSH suppression should be applied in all cases.

Özet

Diferansiye tiroid kanseri (DTK) insidansı yüksek olmakla birlikte mortalitesi oldukça düşüktür. Düşük ve orta riskli DTK'lerinde yetersiz tedavi nedeniyle yeniden yapılan ameliyatlar hastalarda morbidite, mortalite ve maliyetleri artırabilir. Çalışmamızda bu konuda yayınlanmış güncel makaleler incelenip değerlendirilmiştir. Sonuçlarımıza göre, DTK'lerinde yetersiz tedavi nedeniyle morbidite, mortalite ve maliyetler artmaktadır. Bu nedenle, düşük ve orta riskli DTK vakalarında bile, yüksek hacimli endokrin cerrahlar tarafından total veya totale yakın tiroidektomi gibi yeterli ameliyatlar yapılmalı ve tüm vakalarda orta derecede TSH supresyonu uygulanmalıdır.

🔖

Cite This Article

ACAR, H., AKALIN, A. (2023). The effects of reoperations due to inadequate treatment in differentiated thyroid cancers on morbidity, mortality and costs. Pamukkale Tıp Dergisi, Cilt: 16 Sayı: 4, 736–741. https://ajindex.com/articles/963233

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Pizzato M, Li M, Vignat J, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol 2022;10:264-272.
  2. Cavalheiro BG, Shah JP, Randolph GW, et al. Management of recurrent well-differentiated thyroid carcinoma in the neck: a comprehensive review. Cancers 2023;15:923-936.
  3. Scheller B, Culie D, Poissonnet G, Dassonville O, D’Andrea G, Bozec A. Recent advances in the surgical management of thyroid Cancer. Curr Oncol 2023;30:4787-4804.
  4. Coca Pelaz A, Rodrigo JP, Shah JP, et al. Recurrent differentiated thyroid cancer: the current treatment options. Cancers 2023;15:2692-2700.
  5. Nieto HR, Thornton CEM, Brookes K, et al. Recurrence of papillary thyroid cancer: a systematic appraisal of risk factors. Endocrinol Metab 2022;107:1392-1406.
  6. Harries V, Wang LY, McGill M, et al. Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma? Surgery 2020;167:10-17.
  7. Shaunak N, Shinn JR, Rohde SL, Nagup MM, Rohde SL. Risk factors and outcomes of postoperative recurrent well-differentiated thyroid cancer: a single institution’s 15-year experience. Otolaryn–Head and Neck Surg 2020;162:469-475.
  8. Kaliszevsky K, Diakovska D, Woshtczak B, Migon J, Kasprzyk A, Rudnicki J. The occurrence of and predictive factors for multifocality and bilaterality in patients with papillary thyroid microcarcinoma. Medicine 2019;98:e15609.
  9. Shen X, Ding J, Chen H, Cui A, Chen X. Reoperative thyroid surgery: a report of 110 cases. J Surg Con Prac 2019;24:79-84.
  10. Wilson DB, Staren ED, Prinz RA. Thyroid reoperations: indications and risks. Am Surg 1998;64:674-678
  11. Araz M, Özkan E, Gündüz P, Soydal C, Küçük NO, Kır M. Negative histopathological prognostic factors affecting morbidity in t1 differentiated thyroid carcinoma. Cancer Biother Radiopharm 2022;37:56-62.
  12. Christison Lagay ER, Baertschiger RM, Dinauer C, et al. Pediatric differentiated thyroid carcinoma: an update from the APSA Cancer Committee. J Ped Surg 2020;55:2273-228